Gene expression of 61 FFPE tissues of DLBCL patients at high-risk (aaIPI 2 or 3). Gene expression of 61 FFPE tissues of DLBCL patients at high-risk (aaIPI 2 or 3)

Current staging classifications do not accurately predict the benefit of high-dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) for patients with diffuse large B-cell lymphoma (DLBCL) at high risk (age-adjusted International Index [aaIPI] score 2 or 3), who have achieved first complete remission after R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) treatment. We aim to construct a genetic prognostic model for improving individualized risk stratification and response prediction for HDC/ASCT therapy. We identified differentially expressed mRNAs associated with relapse of DLBCL. Overall design: Affymetrix Human U133 Plus 2.0 microarrays (ThermoFisher Scientific, Waltham, MA, USA) identified differentially expressed mRNAs between 34 relapse and 27 relapse-free DLBCL patients.